291 related articles for article (PubMed ID: 35081502)
1. Spop ameliorates diabetic nephropathy through restraining NLRP3 inflammasome.
Wang B; Dai Z; Gao Q; Liu Y; Gu G; Zheng H
Biochem Biophys Res Commun; 2022 Feb; 594():131-138. PubMed ID: 35081502
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
3. NLRP3 inflammasome negatively regulates podocyte autophagy in diabetic nephropathy.
Hou Y; Lin S; Qiu J; Sun W; Dong M; Xiang Y; Wang L; Du P
Biochem Biophys Res Commun; 2020 Jan; 521(3):791-798. PubMed ID: 31703838
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-κB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice.
Song W; Wei L; Du Y; Wang Y; Jiang S
Int Immunopharmacol; 2018 Oct; 63():227-238. PubMed ID: 30107367
[TBL] [Abstract][Full Text] [Related]
5. Artificially Cultivated
Wang C; Hou XX; Rui HL; Li LJ; Zhao J; Yang M; Sun LJ; Dong HR; Cheng H; Chen YP
J Diabetes Res; 2018; 2018():1390418. PubMed ID: 30534570
[TBL] [Abstract][Full Text] [Related]
6. Astragaloside IV ameliorates diabetic nephropathy in
Feng H; Zhu X; Tang Y; Fu S; Kong B; Liu X
Int J Mol Med; 2021 Aug; 48(2):. PubMed ID: 34278447
[TBL] [Abstract][Full Text] [Related]
7. Novel biphenyl diester derivative AB-38b inhibits NLRP3 inflammasome through Nrf2 activation in diabetic nephropathy.
Du L; Wang J; Chen Y; Li X; Wang L; Li Y; Jin X; Gu X; Hao M; Zhu X; Yin X; Lu Q
Cell Biol Toxicol; 2020 Jun; 36(3):243-260. PubMed ID: 31768838
[TBL] [Abstract][Full Text] [Related]
8. Podocyte RNF166 deficiency alleviates diabetic nephropathy by mitigating mitochondria impairment and apoptosis via regulation of CYLD signal.
Hongbo M; Yanjiao D; Shuo W; Kun S; Yanjie L; Mengmeng L
Biochem Biophys Res Commun; 2021 Mar; 545():46-53. PubMed ID: 33545631
[TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-
He J; Cui J; Shi Y; Wang T; Xin J; Li Y; Shan X; Zhu Z; Gao Y
J Diabetes Res; 2023; 2023():7423661. PubMed ID: 37261217
[TBL] [Abstract][Full Text] [Related]
10. [Triptolide inhibits NLRP3 inflammasome activation and ameliorates podocyte epithelial-mesenchymal transition induced by high glucose].
Wu W; Liu BH; Wan YG; Sun W; Liu YL; Wang WW; Fang QJ; Tu Y; Yee HY; Yuan CC; Wan ZY
Zhongguo Zhong Yao Za Zhi; 2019 Dec; 44(24):5457-5464. PubMed ID: 32237395
[TBL] [Abstract][Full Text] [Related]
11. LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy.
Yi H; Peng R; Zhang LY; Sun Y; Peng HM; Liu HD; Yu LJ; Li AL; Zhang YJ; Jiang WH; Zhang Z
Cell Death Dis; 2017 Feb; 8(2):e2583. PubMed ID: 28151474
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic Acid Induces Podocyte Pyroptosis in Diabetic Nephropathy by an Increase of Egr1 Expression via Downregulation of EzH2.
Kim D; Ban KY; Lee GH; Jun HS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373116
[TBL] [Abstract][Full Text] [Related]
13. Huangkui capsule alleviates renal tubular epithelial-mesenchymal transition in diabetic nephropathy via inhibiting NLRP3 inflammasome activation and TLR4/NF-κB signaling.
Han W; Ma Q; Liu Y; Wu W; Tu Y; Huang L; Long Y; Wang W; Yee H; Wan Z; Tang R; Tang H; Wan Y
Phytomedicine; 2019 Apr; 57():203-214. PubMed ID: 30785016
[TBL] [Abstract][Full Text] [Related]
14. Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway.
Lv C; Cheng T; Zhang B; Sun K; Lu K
Ren Fail; 2023 Dec; 45(1):2165103. PubMed ID: 36938748
[No Abstract] [Full Text] [Related]
15. Sarsasapogenin alleviates diabetic nephropathy through suppression of chronic inflammation by down-regulating PAR-1: In vivo and in vitro study.
Tang ZZ; Zhang YM; Zheng T; Huang TT; Ma TF; Liu YW
Phytomedicine; 2020 Nov; 78():153314. PubMed ID: 32882582
[TBL] [Abstract][Full Text] [Related]
16. Irbesartan ameliorates diabetic nephropathy by activating the Nrf2/Keap1 pathway and suppressing NLRP3 inflammasomes in vivo and in vitro.
Li Y; Long W; Zhang H; Zhao M; Gao M; Guo W; Yu L
Int Immunopharmacol; 2024 Apr; 131():111844. PubMed ID: 38503013
[TBL] [Abstract][Full Text] [Related]
17. STING deletion alleviates podocyte injury through suppressing inflammation by targeting NLRP3 in diabetic kidney disease.
Yang X; Chen Z; Luo Z; Yang D; Hao Y; Hu J; Feng J; Zhu Z; Luo Q; Zhang Z; Liang W; Ding G
Cell Signal; 2023 Sep; 109():110777. PubMed ID: 37329999
[TBL] [Abstract][Full Text] [Related]
18. FOXM1-activated SIRT4 inhibits NF-κB signaling and NLRP3 inflammasome to alleviate kidney injury and podocyte pyroptosis in diabetic nephropathy.
Xu X; Zhang L; Hua F; Zhang C; Zhang C; Mi X; Qin N; Wang J; Zhu A; Qin Z; Zhou F
Exp Cell Res; 2021 Nov; 408(2):112863. PubMed ID: 34626587
[TBL] [Abstract][Full Text] [Related]
19. Podocyte-specific silencing of acid sphingomyelinase gene to abrogate hyperhomocysteinemia-induced NLRP3 inflammasome activation and glomerular inflammation.
Huang D; Kidd JM; Zou Y; Wu X; Li N; Gehr TWB; Li PL; Li G
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F988-F1003. PubMed ID: 38634138
[TBL] [Abstract][Full Text] [Related]
20. Optineurin inhibits NLRP3 inflammasome activation by enhancing mitophagy of renal tubular cells in diabetic nephropathy.
Chen K; Feng L; Hu W; Chen J; Wang X; Wang L; He Y
FASEB J; 2019 Mar; 33(3):4571-4585. PubMed ID: 30571313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
